Inovio Pharmaceuticals Inc. [INO] moved down -3.85: Why It’s Important

Related

Inovio Pharmaceuticals Inc. [NASDAQ: INO] slipped around -0.2 points on Friday, while shares priced at $4.99 at the close of the session, down -3.85%. The company report on December 14, 2021 that INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18.

INOVIO completes enrollment of REVEAL2.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Compared to the average trading volume of 4.13M shares, INO reached a trading volume of 7254841 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Inovio Pharmaceuticals Inc. [INO]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $13.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for Inovio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on December 29, 2021. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $9 to $8. The new note on the price target was released on September 10, 2021, representing the official price target for Inovio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $9, while Jefferies analysts kept a Hold rating on INO stock.

The Average True Range (ATR) for Inovio Pharmaceuticals Inc. is set at 0.38, with the Price to Sales ratio for INO stock in the period of the last 12 months amounting to 159.12. The Price to Book ratio for the last quarter was 2.31, with the Price to Cash per share for the same quarter was set at 1.91.

How has INO stock performed recently?

Inovio Pharmaceuticals Inc. [INO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.93. With this latest performance, INO shares dropped by -24.39% in over the last four-week period, additionally sinking by -44.68% over the last 6 months – not to mention a drop of -43.62% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 28.58, with the RSI for the last a single of trading hit 23.27, and the three-weeks RSI is set at 32.20 for Inovio Pharmaceuticals Inc. [INO]. The present Moving Average for the last 50 days of trading for this stock 6.64, while it was recorded at 5.29 for the last single week of trading, and 7.75 for the last 200 days.

Inovio Pharmaceuticals Inc. [INO]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc. [INO] shares currently have an operating margin of -1760.60. Inovio Pharmaceuticals Inc.’s Net Margin is presently recorded at -2245.39.

Return on Total Capital for INO is now -43.13, given the latest momentum, and Return on Invested Capital for the company is -55.59. Return on Equity for this stock declined to -71.64, with Return on Assets sitting at -47.85. When it comes to the capital structure of this company, Inovio Pharmaceuticals Inc. [INO] has a Total Debt to Total Equity ratio set at 8.47. Additionally, INO Total Debt to Total Capital is recorded at 7.81, with Total Debt to Total Assets ending up at 7.18. Long-Term Debt to Equity for the company is recorded at 7.96, with the Long-Term Debt to Total Capital now at 7.34.

Reflecting on the efficiency of the workforce at the company, Inovio Pharmaceuticals Inc. [INO] managed to generate an average of -$635,157 per employee. Receivables Turnover for the company is 0.70 with a Total Asset Turnover recorded at a value of 0.02.Inovio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.50 and a Current Ratio set at 9.50.

Earnings analysis for Inovio Pharmaceuticals Inc. [INO]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inovio Pharmaceuticals Inc. go to 45.80%.

>> 7 Top Picks for the Post-Pandemic Economy <<

Insider trade positions for Inovio Pharmaceuticals Inc. [INO]

There are presently around $380 million, or 37.80% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: BLACKROCK INC. with ownership of 18,369,653, which is approximately 1.089% of the company’s market cap and around 1.65% of the total institutional ownership; VANGUARD GROUP INC, holding 10,956,586 shares of the stock with an approximate value of $54.67 million in INO stocks shares; and STATE STREET CORP, currently with $54.63 million in INO stock with ownership of nearly 22.904% of the company’s market capitalization.

Positions in Inovio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 90 institutional holders increased their position in Inovio Pharmaceuticals Inc. [NASDAQ:INO] by around 7,674,996 shares. Additionally, 84 investors decreased positions by around 4,261,972 shares, while 64 investors held positions by with 64,165,800 shares. The mentioned changes placed institutional holdings at 76,102,768 shares, according to the latest SEC report filing. INO stock had 32 new institutional investments in for a total of 694,003 shares, while 24 institutional investors sold positions of 784,657 shares during the same period.